Sucralfate
Market, by Formulation (Tablet and Liquid), by Indication (Gastric Ulcers,
Duodenal Ulcers, Gastro Esophageal Reflux Disease (GERD), and Other
Indications), and by Region (North America, Europe, Asia Pacific, Latin
America, Middle East, and Africa) - Size, Share, Outlook, and Opportunity
Analysis 2018 – 2026
Sucralfate is the generic form of
the brand-name drug, Carafate. It is a prescription medicine used to treat
ulcers of the upper gastrointestinal tract, peptic ulcer disease, and to
prevent reoccurrence of ulcers. Sucralfate is a hydroxy aluminum salt of
sucrose octasulfate that functions as a local mucosal adherent. It forms a
coating over ulcers by sticking to the affected area, which protects the area
from acid and enzymes and helps ulcers to heal more quickly.
Sucralfate can also be used in
treating ulcers and upper gastrointestinal disorders of dog, horse, and cat,
which may arise due to drugs (particularly non-steroidal anti-inflammatory
drugs (NSAIDs) and corticosteroids), toxic chemical ingestion, liver disease,
renal failure, carcinoma, stress (trauma, shock, sepsis, and burns), and
inflammatory bowel disease.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2325
Sucralfate Market Drivers
Increasing research and
development activities for discovering new medicine using sucralfate is
expected to propel growth of the sucralfate market. For instance, according to
the American Broncho Esophagological Association report in April 2018, use of sucralfate
along with honey aids in treatment of esophageal injury in infants and
children. Esophageal injury in infants and children is associated with
consumption of Button Batteries (BB), small disc-shaped batteries commonly
found in toys. Use of sucralfate with honey can help in mitigation of the
button batteries and allows symptomatic relief from esophageal injury.
Sucralfate Market Restraint
Drug shortages are projected to
hinder growth of the sucralfate market. For instance, according to Drug
Shortages Canada, report of September 2018, APO-SUCRALFATE - TAB 1G (APOTEX
INC) that contained sucralfate was not available due to disruption in the
manufacturing of the drug. The drug is used to treat peptic ulcer and gastro esophageal
reflux disease (GERD).
Sucralfate Market – Regional
Analysis
On the basis of region, the
global sucralfate market is segmented into North America, Latin America,
Europe, Asia Pacific, Middle East, and Africa.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/sucralfate-market-2325
North America is expected to hold
dominant position in the sucralfate market, owing to increasing number of
clinical studies. For instance, University of Texas is conducting a clinical
phase II study on sucralfate to improve oral intake in children with infectious
oral ulcers. The study is expected to be completed by June 2019.
By 2026, Asia Pacific is expected
to witness significant growth in the global sucralfate market due to increasing
prevalence of H. pylori associated peptic ulcer disease, gastric cancer, and
gastric mucosa-associated lymphoid tissue (MALT) lymphoma.
Key players operating in the
global sucralfate market include, SRL Pharma, Nitika Chemicals., Teva
Pharmaceutical Industries Ltd., Lisapharma S.p.A, Aptalis Pharma US, Inc.,
Uniprix Group, Rx Outreach, Abcam Plc, and Quimica Alkano.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2325
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment